RU2006118789A - 2-цианопирролидинкарбоксамидное соединение - Google Patents
2-цианопирролидинкарбоксамидное соединение Download PDFInfo
- Publication number
- RU2006118789A RU2006118789A RU2006118789/04A RU2006118789A RU2006118789A RU 2006118789 A RU2006118789 A RU 2006118789A RU 2006118789/04 A RU2006118789/04 A RU 2006118789/04A RU 2006118789 A RU2006118789 A RU 2006118789A RU 2006118789 A RU2006118789 A RU 2006118789A
- Authority
- RU
- Russia
- Prior art keywords
- lower alkyl
- optionally substituted
- substituent
- amino
- compound according
- Prior art date
Links
- -1 2-Cyanopyrrolidinecarboxamide compound Chemical class 0.000 title claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000001424 substituent group Chemical group 0.000 claims 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000001589 carboacyl group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000005241 heteroarylamino group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 3
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- AUEFMDKGVXZKPL-BUMIUHBFSA-N (2s)-1-[(1r,2s,4r,5r)-5-amino-3-azabicyclo[2.2.1]heptane-2-carbonyl]pyrrolidine-2-carbonitrile;dihydrochloride Chemical compound Cl.Cl.O=C([C@H]1N[C@@]2([H])[C@H](N)C[C@@]1(C2)[H])N1CCC[C@H]1C#N AUEFMDKGVXZKPL-BUMIUHBFSA-N 0.000 claims 1
- IXYABBFPMPPMPO-OWMZXZORSA-N (2s)-1-[(1r,4r,5r,7s)-4-hydroxy-6-azabicyclo[3.2.1]octane-7-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@H]1N[C@@]2(C[C@]1(CC[C@H]2O)[H])[H])N1CCC[C@H]1C#N IXYABBFPMPPMPO-OWMZXZORSA-N 0.000 claims 1
- UTSAVWUDUPXYMN-AFLYGPLOSA-N (2s)-1-[(1s,2s,4r,5r)-5-(2-hydroxyethoxy)-3-azabicyclo[2.2.1]heptane-2-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@H]1N[C@@]2([H])[C@H](OCCO)C[C@@]1(C2)[H])N1CCC[C@H]1C#N UTSAVWUDUPXYMN-AFLYGPLOSA-N 0.000 claims 1
- HBURXUXZLKNVTI-QSWPLQKNSA-N (2s)-1-[(1s,2s,4r,5r)-5-hydroxy-3-azabicyclo[2.2.1]heptane-2-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@H]1N[C@@]2([H])[C@H](O)C[C@@]1(C2)[H])N1CCC[C@H]1C#N HBURXUXZLKNVTI-QSWPLQKNSA-N 0.000 claims 1
- HBURXUXZLKNVTI-AZDRDEPNSA-N (2s)-1-[(1s,2s,4r,5s)-5-hydroxy-3-azabicyclo[2.2.1]heptane-2-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@H]1N[C@@]2([H])[C@@H](O)C[C@@]1(C2)[H])N1CCC[C@H]1C#N HBURXUXZLKNVTI-AZDRDEPNSA-N 0.000 claims 1
- BCSFFROFYZFBMX-JVDJTQHISA-N (2s)-1-[(1s,2s,4r,5z)-5-hydroxyimino-3-azabicyclo[2.2.1]heptane-2-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@H]1N[C@@]2([H])C(=N\O)/C[C@@]1(C2)[H])N1CCC[C@H]1C#N BCSFFROFYZFBMX-JVDJTQHISA-N 0.000 claims 1
- HIFIXNJGFRGAKV-AFFIPDDESA-N (2s)-1-[(1s,2s,4s,5r,6s)-5,6-dihydroxy-3-azabicyclo[2.2.2]octane-2-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@@H]1[C@]2([H])CC[C@@]([C@H]([C@H]2O)O)(N1)[H])N1CCC[C@H]1C#N HIFIXNJGFRGAKV-AFFIPDDESA-N 0.000 claims 1
- BSTOTEXATQCDHE-WMYFGTORSA-N (2s)-1-[(1s,3s,4s,5r)-5-hydroxy-2-azabicyclo[2.2.2]octane-3-carbonyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C([C@@H]1[C@]2([H])CC[C@@](C[C@H]2O)(N1)[H])N1CCC[C@H]1C#N BSTOTEXATQCDHE-WMYFGTORSA-N 0.000 claims 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003906010 | 2003-10-31 | ||
| AU2003906010A AU2003906010A0 (en) | 2003-10-31 | DPP-IV Inhibitor | |
| AU2004900961A AU2004900961A0 (en) | 2004-02-25 | DPP-IV inhibitor | |
| AU2004900961 | 2004-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006118789A true RU2006118789A (ru) | 2007-12-10 |
Family
ID=34553068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006118789/04A RU2006118789A (ru) | 2003-10-31 | 2004-10-29 | 2-цианопирролидинкарбоксамидное соединение |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7186731B2 (enExample) |
| EP (1) | EP1737863B1 (enExample) |
| JP (1) | JP4636021B2 (enExample) |
| KR (1) | KR20060100390A (enExample) |
| AR (1) | AR046313A1 (enExample) |
| AT (1) | ATE419250T1 (enExample) |
| BR (1) | BRPI0415587A (enExample) |
| CA (1) | CA2543533A1 (enExample) |
| CO (1) | CO5690603A2 (enExample) |
| DE (1) | DE602004018837D1 (enExample) |
| ES (1) | ES2320557T3 (enExample) |
| IL (1) | IL175214A0 (enExample) |
| MX (1) | MXPA06004797A (enExample) |
| NO (1) | NO20062517L (enExample) |
| RU (1) | RU2006118789A (enExample) |
| TW (1) | TW200528440A (enExample) |
| WO (1) | WO2005042533A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2327857T3 (es) | 2004-05-12 | 2009-11-04 | Pfizer Products Inc. | Derivados de prolina y su uso como inhibidores de la dipeptidil peptidasa iv. |
| CN101193852A (zh) * | 2005-02-18 | 2008-06-04 | 因诺迪亚有限公司 | 4-羟基异亮氨酸类似物及其用途 |
| BRPI0611550A2 (pt) * | 2005-03-22 | 2009-01-13 | Innodia Inc | uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| EP1917001A2 (en) * | 2005-08-11 | 2008-05-07 | F.Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| WO2007107008A1 (en) * | 2006-03-22 | 2007-09-27 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
| WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
| JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
| US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| NZ709260A (en) | 2012-12-21 | 2016-07-29 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| EP2970252B1 (en) | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| WO2014140075A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| CN108047240B (zh) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| IT201700059292A1 (it) * | 2017-05-31 | 2018-12-01 | Univ Pisa | Derivati 1,3-diaza-4-ossa-[3.3.1]-biciclici, loro preparazione e uso come medicinale, in particolare per il trattamento del diabete |
| JP7352551B2 (ja) | 2018-08-08 | 2023-09-28 | 住友ファーマ株式会社 | 光学活性な架橋型ピペリジン誘導体 |
| WO2020045334A1 (ja) | 2018-08-27 | 2020-03-05 | 大日本住友製薬株式会社 | 光学活性なアザビシクロ環誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002360732A1 (en) * | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
-
2004
- 2004-10-28 TW TW093132734A patent/TW200528440A/zh unknown
- 2004-10-29 EP EP04793389A patent/EP1737863B1/en not_active Expired - Lifetime
- 2004-10-29 DE DE602004018837T patent/DE602004018837D1/de not_active Expired - Fee Related
- 2004-10-29 JP JP2006518489A patent/JP4636021B2/ja not_active Expired - Fee Related
- 2004-10-29 BR BRPI0415587-4A patent/BRPI0415587A/pt not_active IP Right Cessation
- 2004-10-29 ES ES04793389T patent/ES2320557T3/es not_active Expired - Lifetime
- 2004-10-29 KR KR1020067007974A patent/KR20060100390A/ko not_active Withdrawn
- 2004-10-29 US US10/975,524 patent/US7186731B2/en not_active Expired - Fee Related
- 2004-10-29 RU RU2006118789/04A patent/RU2006118789A/ru not_active Application Discontinuation
- 2004-10-29 AR ARP040104001A patent/AR046313A1/es not_active Application Discontinuation
- 2004-10-29 MX MXPA06004797A patent/MXPA06004797A/es not_active Application Discontinuation
- 2004-10-29 CA CA002543533A patent/CA2543533A1/en not_active Abandoned
- 2004-10-29 AT AT04793389T patent/ATE419250T1/de not_active IP Right Cessation
- 2004-10-29 WO PCT/JP2004/016469 patent/WO2005042533A2/en not_active Ceased
-
2006
- 2006-04-26 CO CO06039525A patent/CO5690603A2/es not_active Application Discontinuation
- 2006-04-26 IL IL175214A patent/IL175214A0/en unknown
- 2006-05-31 NO NO20062517A patent/NO20062517L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1737863A2 (en) | 2007-01-03 |
| MXPA06004797A (es) | 2006-07-03 |
| EP1737863B1 (en) | 2008-12-31 |
| BRPI0415587A (pt) | 2007-01-02 |
| AR046313A1 (es) | 2005-11-30 |
| WO2005042533A3 (en) | 2005-09-01 |
| US20050137224A1 (en) | 2005-06-23 |
| TW200528440A (en) | 2005-09-01 |
| ATE419250T1 (de) | 2009-01-15 |
| WO2005042533A2 (en) | 2005-05-12 |
| CA2543533A1 (en) | 2005-05-12 |
| ES2320557T3 (es) | 2009-05-25 |
| IL175214A0 (en) | 2006-09-05 |
| NO20062517L (no) | 2006-07-21 |
| KR20060100390A (ko) | 2006-09-20 |
| CO5690603A2 (es) | 2006-10-31 |
| US7186731B2 (en) | 2007-03-06 |
| JP2007510619A (ja) | 2007-04-26 |
| JP4636021B2 (ja) | 2011-02-23 |
| DE602004018837D1 (de) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006118789A (ru) | 2-цианопирролидинкарбоксамидное соединение | |
| SI3045206T1 (en) | A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase | |
| BRPI0017548A2 (pt) | Composto, e, processo para a preparação de um composto | |
| KR20250065935A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| RU2585622C3 (ru) | Тетрациклические соединения | |
| SE9901573D0 (sv) | New compounds | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| FI3909584T3 (fi) | Pyrimidiiniyhdiste tai sen suola | |
| BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz | |
| US5462970A (en) | Polyamines and anti-diarrheal and gastrointestinal anti-spasmodic pharmaceutical compositions and methods of treatment | |
| ES2323137T3 (es) | Composicion antiparasitaria que contiene una sal de amina organica de closantel. | |
| TNSN05080A1 (en) | NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published) | |
| NO891390L (no) | Fremgangsmaate for fremstilling av bicykliske aminforbindelser. | |
| CA2487252A1 (en) | Esters in position 20 of camptothecins | |
| MX2025003934A (es) | Métodos para preparar derivados de carbamato | |
| SE9901572D0 (sv) | New compounds | |
| EA202100186A2 (ru) | Вакцина и способ защиты от коронавирусной инфекции | |
| SE9900190D0 (sv) | New compounds | |
| RU2003124760A (ru) | Производные миканолида, их получение и их терапевтические применения | |
| KR950702561A (ko) | 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs) | |
| AU2006341592A1 (en) | Intramuscular antiviral treatments | |
| RU2170576C1 (ru) | Гидрохлориды замещенных ацетиленовых аминоспиртов, обладающие антигалоперидоловой активностью | |
| KR900016092A (ko) | 아미노산 에스테르, 이의 제조방법, 이를 함유하는 약제, 및 이의 용도 | |
| RU2184542C2 (ru) | Гидрохлорид 1-фенил-1-циклопентил-4-пиперидино-2-бутин-1-ола (пентифин), обладающий активностью при лечении и предупреждении паркинсонизма | |
| BR0317292A (pt) | Derivados de amida de ácido antranìlico e seu uso farmacêutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081023 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081023 |